Phase 2 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are planning to start a standard aromatase inhibitor (AI) medication and expected to take it for at least 24 weeks, either for stage 0–3 breast cancer or to reduce the risk of developing breast cancer
- People who are also taking certain other medications alongside AI therapy — including GnRHa (a hormone-related treatment), bone-protecting medications, anti-HER2 therapy, ribociclib, or PARP inhibitors — may still be eligible
- People whose average joint pain over the past 7 days has been rated between 0 and 6 on a scale of 0 to 10
- People who are able to swallow and take oral (by mouth) medication
- People who are able to read and understand English
- People who are aware of their diagnosis, understand what the study involves, and are able to sign a consent form
Who may not be able to join:
- People whose breast cancer has spread to distant parts of the body (metastatic breast cancer)
- People who are currently taking or planning to take abemaciclib (a cancer medication) during the study period
- People who are currently receiving or planning to receive chemotherapy or immunotherapy during the study period
- People who are pregnant, breastfeeding, or planning to become pregnant during the study period
- People with a known active inflammatory bowel disease
- People who have had a colectomy (surgical removal of part or all of the colon) or gastric bypass surgery
- People who have previously taken AI therapy, except if it was used as part of fertility treatment
- People who are planning to use prebiotic supplements during the study period
- People who are using estrogen supplements (other than vaginal estrogen products)
- People who are currently participating in another clinical trial involving an investigational (unapproved) treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Norah L Henry, M.D., University of Michigan Rogel Cancer Center
Phone: 1-800-865-1125
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Proportion of patients who took at least 70% of resistant potato starch (RPS) doses per protocol
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.